首页|鳖甲煎丸调控EGFR/MAPK/ERK通路对MHCC-97H肝癌细胞的影响

鳖甲煎丸调控EGFR/MAPK/ERK通路对MHCC-97H肝癌细胞的影响

扫码查看
目的 探讨鳖甲煎丸通过miR-885-5p对表皮生长因子受体(EGFR)/丝裂原激活蛋白激酶(MAPK)/细胞外信号调节激酶(ERK)信号通路的靶向调控对MHCC-97H肝癌细胞的影响及作用机制。方法 SPF级SD大鼠10只随意分为空白组和鳖甲煎丸(1。1 g/kg)组,制备空白及鳖甲煎丸含药血清。取对数生长期的MHCC-97H细胞,分为模型组、不同质量分数(5%、10%、15%、20%)空白血清梯度组和鳖甲煎丸含药血清梯度组,以及不含细胞的空白组。CCK-8法检测细胞增殖,筛选含药血清最佳干预时间及质量分数。将MHCC-97H细胞分为空白对照组(不做任何处理)、鳖甲煎丸含药血清组(20%鳖甲煎丸含药血清)、miR-885-5p mimics组(转染miR-885-5p mimics)、miR-NC组(转染miR-885-5p阴性对照物)、鳖甲煎丸含药血清+miR-885-5p mimics组(20%鳖甲煎丸含药血清和转染miR-885-5p mimics),各组细胞均培养72 h。采用双荧光素酶报告实验验证miR-885-5p与EGFR的靶向关系。CCK-8法检测细胞增殖,细胞划痕实验及Transwell侵袭实验检测细胞迁移和侵袭能力,Annexin V-APC/PI双染色法检测细胞凋亡水平,实时荧光定量聚合酶链反应(RT-qPCR)检测miR-885-5p、EGFR、MAPK的激酶(MEK)、ERK1、ERK2 mRNA表达水平;蛋白质印迹法检测EGFR、磷酸化的EGFR(p-EGFR)、MEK、磷酸化的MEK(p-MEK)、ERK1、ERK2、磷酸化的ERK1(p-ERK1)、磷酸化的ERK2(p-ERK2)、基质金属蛋白酶1(MMP1)、细胞周期蛋白D1(CyclinD1)蛋白表达;通过皮下注射法建立裸鼠MHCC-97H肝癌细胞皮下瘤模型,观察不同剂量鳖甲煎丸(0。55、1。1、2。2g/kg)对裸鼠肝癌皮下瘤的抑制效果。结果 筛选出鳖甲煎丸含药血清最佳干预质量分数及时间为20%、72 h,同时,双荧光素酶报告实验显示,miR-885-5p可以直接靶向结合EGFR;各项实验报告显示空白对照组和miR-NC组比较,差异均无统计学意义(P>0。05)。与空白对照组比较,鳖甲煎丸含药血清组、miR-885-5p mimics组和鳖甲煎丸含药血清+miR-885-5p mimics组MHCC-97H肝癌细胞增殖率明显降低(P<0。01),迁移和侵袭能力明显下降(P<0。05,P<0。01),同时,与细胞增殖、侵袭密切相关的蛋白CyclinD1和MMP1的蛋白表达明显下调(P<0。05,P<0。01),晚期凋亡率和总凋亡率均明显升高,促进细胞凋亡(P<0。01);鳖甲煎丸含药血清组、miR-885-5p mimics组和鳖甲煎丸含药血清+miR-885-5p mimics组明显上调miR-885-5p mRNA(P<0。01),抑制EGFR、MEK、ERK1、ERK2 mRNA表达(P<0。05,P<0。01),抑制EGFR、MEK、ERK1、ERK2磷酸化激活(P<0。01),其中,鳖甲煎丸含药血清+miR-885-5p mimics组效果最好(P<0。05,P<0。01)。裸鼠肝癌皮下瘤模型验证了鳖甲煎丸可抑制裸鼠肝癌皮下瘤生长。结论 鳖甲煎丸可促进MHCC-97H肝癌细胞凋亡,抑制其增殖、侵袭和迁移,其作用机制可能和通过miR-885-5p靶向调控EGFR/MAPK/ERK信号通路有关。
The effect of Biejiajian Pills on regulating the EGFR/MAPK/ERK pathway in MHCC-97H liver cancer cells
Objective We aimed to investigate the effects of Biejiajian Pills on MHCC-97H hepatoma cells and whether Biejiajian Pills regulate the epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathway through miR-885-5p.Methods SPF SD rats (n = 10) were randomly divided into the blank group and the Biejiajian Pills (1.1 g/kg) group to prepare blank and Biejiajian Pills-containing serum. MHCC-97H cells in the logarithmic growth phase were divided into the model group, blank serum groups with different concentrations (5%, 10%, 15%, and 20%), the serum containing Biejiajian Pills group, and the blank group without cells. Cell proliferation was detected by the CCK-8 assay, and the optimal intervention time and concentration of drug-containing serum were screened. MHCC-97H cells were divided into the blank control group (no intervention), the Biejiajian Pills-containing serum group (20% Biejiajian Pills-containing serum), the miR-885-5p mimics group (transfected with miR-885-5p mimics), the miR-NC group (transfected with miR-885-5p NC), and the Biejiajian Pills-containing serum + miR-885-5p mimics group (treated with 20% Biejiajian Pills-containing serum and transfected with miR-885-5p mimics). Cells in each group were cultured for 72 hours. A dual luciferase reporter assay was conducted to verify the targeting relationship between miR-885-5p and EGFR. Cell proliferation was detected by the CCK-8 assay, cell migration and invasion abilities were detected by the cell scratch assay and the Transwell invasion assay. Annexin V-APC/PI double staining was performed to detect the apoptosis level, and real-time fluorescence quantitative PCR (RT-qPCR) analysis was conducted to determine the mRNA expression levels of miR-885-5p, EGFR, MEK, and ERK1/2. The expression levels of EGFR, p-EGFR, MEK, p-MEK, ERK1/2, p-ERK1/2, matrix metalloproteinase 1 (MMP1), and CyclinD1 were determined by Western blotting analysis. The subcutaneous tumor model of MHCC-97H hepatoma cells in nude mice was established by subcutaneous injection to observe the inhibitory effect of Biejiajian Pills of different doses(0.55,1.1,2.2 g/kg).Results The optimal concentration and intervention time of Biejiajian Pills-containing serum were 20% and 72 hours, respectively. Meanwhile, the dual luciferase reporter assay showed that miR-885-5p could directly target EGFR. No statistical significances between the blank control group and the miR-NC group were observed (P>0.05). Compared with the blank control group, the proliferation rates of MHCC-97H hepatoma cells in the Biejiajian Pills-containing serum group, the miR-885-5p mimics group, and the Biejiajian Pills-containing serum + miR-885-5p mimics group were significantly decreased (P<0.01), and their migration and invasion abilities were significantly decreased (P<0.05, P<0.01). At the same time, the protein expression levels of CyclinD1 and MMP1, which are closely related to cell proliferation and invasion, were significantly downregulated (P<0.05, P<0.01). The proportions of late apoptotic cells and the proportion of total apoptotic cells were significantly increased (P<0.01). In the Biejiajian Pills-containing serum group, the miR-885-5p mimics group, and the Biejiajian Pills-containing serum + miR-885-5p mimics group, miR-885-5p mRNA was significantly upregulated (P<0.01) and EGFR, MEK, and ERK1/2 were significantly downregulated at the mRNA level (P<0.05, P<0.01). EGFR, MEK, and ERK1/2 phosphorylation was inhibited (P<0.01), and the Biejiajian Pills-containing serum + miR-885-5p mimics group showed the best effect (P<0.05, P<0.01). The subcutaneous liver tumor model in nude mice verified that Biejiajian Pills can inhibit tumor growth in a dose-dependent manner. Conclusion Biejiajian Pills can promote apoptosis of MHCC-97H hepatoma cells and inhibit their proliferation, invasion, and migration. The mechanism may be related to the targeted regulation of the EGFR/MAPK/ERK signaling pathway by miR-885-5p.

Biejiajian PillsmiR-885-5pepidermal growth factor receptormitogen-activated protein kinaseMHCC-97H hepatoma cellsnude micesubcutaneous tumor

伍梦思、刘华、谭年花、李杳瑶、丁琳、夏宇、陈扬、陈斌

展开 >

湖南中医药大学第一中医临床学院 长沙 410007

湖南中医药大学中西医结合学院

解放军总医院第八医学中心

鳖甲煎丸 miR-885-5p 表皮生长因子受体 丝裂原激活蛋白激酶 MHCC-97H肝癌细胞 裸鼠 皮下瘤

中国博士后科学基金湖南省自然科学基金湖南省临床医学研究中心基地项目湖南中医药大学研究生创新课题

2022M7211272023JJ404872021SK40232022CX29

2024

北京中医药大学学报
北京中医药大学

北京中医药大学学报

CSTPCD北大核心
影响因子:1.568
ISSN:1006-2157
年,卷(期):2024.47(3)
  • 1
  • 31